Hub ap­peal: As­traZeneca is mar­shal­ing 350-plus R&D troops in new South San Fran­cis­co cam­pus

In bio­phar­ma, the big glob­al hubs have be­come ir­re­sistible at­trac­tions as tro­phy lo­ca­tions suck in thou­sands of R&D jobs from the gi­ants as well as star­tups. And As­traZeneca, which has been push­ing an R&D makeover for years now, is once again help­ing to dri­ve that trend by pulling most of its Bay Area ops in­to a gleam­ing new fa­cil­i­ty now un­der con­struc­tion in the South San Fran­cis­co hub.

As­traZeneca, which has been build­ing a $500 mil­lion HQ in the UK’s Gold­en Tri­an­gle, is re­lo­cat­ing more than 350 staffers in­to the li­on’s share of a new 230,000 square foot project. That will in­clude re­searchers for As­traZeneca, its big sub­sidiary Med­Im­mune, Ac­er­ta Phar­ma (As­traZeneca paid $4 bil­lion for a 55% stake) and the Pearl res­pi­ra­to­ry ops it ac­quired in 2013.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.